{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:55:52Z","timestamp":1790502952428,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013996","name":"Global Health Innovative Technology Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19KK0206"],"award-info":[{"award-number":["JP19KK0206"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20H03481"],"award-info":[{"award-number":["JP20H03481"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16H05816"],"award-info":[{"award-number":["JP16H05816"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["T2019-254"],"award-info":[{"award-number":["T2019-254"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parasitology International"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.parint.2021.102525","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T02:34:06Z","timestamp":1639017246000},"page":"102525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation"],"prefix":"10.1016","volume":"87","author":[{"given":"Mayumi","family":"Tachibana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eizo","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jetsumon","family":"Sattabongkot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Ishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Culleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomi","family":"Torii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parint.2021.102525_bb0005","series-title":"WHO Press 2020","first-page":"2020","author":"WHO, World Malaria Report","year":"2020"},{"issue":"1","key":"10.1016\/j.parint.2021.102525_bb0010","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12879-020-05046-y","article-title":"Prevalence and risk factors related to poor outcome of patients with severe plasmodium vivax infection: a systematic review, meta-analysis, and analysis of case reports","volume":"20","author":"Kotepui","year":"2020","journal-title":"BMC Infect. Dis."},{"issue":"8","key":"10.1016\/j.parint.2021.102525_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003071","article-title":"Is plasmodium vivax malaria a severe malaria?: a systematic review and meta-analysis","volume":"8","author":"Naing","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"6","key":"10.1016\/j.parint.2021.102525_bb0020","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4269\/ajtmh.1982.31.1291","article-title":"Demonstration of hypnozoites in sporozoite-transmitted plasmodium vivax infection","volume":"31","author":"Krotoski","year":"1982","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"3","key":"10.1016\/j.parint.2021.102525_bb0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1710775","article-title":"Single-dose Tafenoquine to prevent relapse of plasmodium vivax malaria","volume":"380","author":"Lacerda","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.parint.2021.102525_bb0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa1802537","article-title":"Tafenoquine versus primaquine to prevent relapse of plasmodium vivax malaria","volume":"380","author":"Llanos-Cuentas","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.parint.2021.102525_bb0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pt.2017.10.009","article-title":"Advancing research models and technologies to overcome biological barriers to plasmodium vivax control","volume":"34","author":"Armistead","year":"2018","journal-title":"Trends Parasitol."},{"issue":"9988","key":"10.1016\/j.parint.2021.102525_bb0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"S.C.T.P. RTS","year":"2015","journal-title":"Lancet"},{"issue":"10287","key":"10.1016\/j.parint.2021.102525_bb0045","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.parint.2021.102525_bb0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","article-title":"Malaria vaccines: recent advances and new horizons","volume":"24","author":"Draper","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.parint.2021.102525_bb0055","series-title":"Malaria Vaccine Technology Roadmap","author":"M.V.F. Group","year":"2013"},{"key":"10.1016\/j.parint.2021.102525_bb0060","first-page":"1","article-title":"Transmission-blocking vaccines: harnessing herd immunity for malaria elimination","author":"Duffy","year":"2021","journal-title":"Expert Rev. Vaccines"},{"issue":"4","key":"10.1016\/j.parint.2021.102525_bb0065","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0014-4894(58)90036-5","article-title":"Changes in infectiousness of malarial gametocytes. II. Analysis of the possible causative factors","volume":"7","author":"Huff","year":"1958","journal-title":"Exp. Parasitol."},{"issue":"5572","key":"10.1016\/j.parint.2021.102525_bb0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/263057a0","article-title":"Malaria transmission blocked by immunisation with gametes of the malaria parasite","volume":"263","author":"Carter","year":"1976","journal-title":"Nature"},{"issue":"4258","key":"10.1016\/j.parint.2021.102525_bb0075","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1126\/science.959832","article-title":"Successful immunization against the sexual stages of plasmodium gallinaceum","volume":"193","author":"Gwadz","year":"1976","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.parint.2021.102525_bb0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0166-6851(84)90116-6","article-title":"Characterization of antigens on mosquito midgut stages of plasmodium gallinaceum. III. Changes in zygote surface proteins during transformation to mature ookinete","volume":"13","author":"Carter","year":"1984","journal-title":"Mol. Biochem. Parasitol."},{"issue":"2","key":"10.1016\/j.parint.2021.102525_bb0085","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0166-6851(85)90032-5","article-title":"Biosynthesis of two stage-specific membrane proteins during transformation of plasmodium gallinaceum zygotes into ookinetes","volume":"14","author":"Kumar","year":"1985","journal-title":"Mol. Biochem. Parasitol."},{"issue":"5","key":"10.1016\/j.parint.2021.102525_bb0090","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1084\/jem.162.5.1460","article-title":"Sequential expression of antigens on sexual stages of plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito","volume":"162","author":"Vermeulen","year":"1985","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.parint.2021.102525_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057909","article-title":"Qualification of standard membrane-feeding assay with plasmodium falciparum malaria and potential improvements for future assays","volume":"8","author":"Miura","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.parint.2021.102525_bb0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41541-021-00309-4","article-title":"Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen","volume":"6","author":"Bender","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.parint.2021.102525_bb0105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fimmu.2017.00126","article-title":"What is known about the immune response induced by plasmodium vivax malaria vaccine candidates?","volume":"8","author":"Lopez","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.parint.2021.102525_bb0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1475-2875-5-68","article-title":"Population dynamics of sporogony for plasmodium vivax parasites from western Thailand developing within three species of colonized Anopheles mosquitoes","volume":"5","author":"Zollner","year":"2006","journal-title":"Malar. J."},{"issue":"1","key":"10.1016\/j.parint.2021.102525_bb0115","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/imr.12828","article-title":"Immunity against sexual stage plasmodium falciparum and plasmodium vivax parasites","volume":"293","author":"de Jong","year":"2020","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.parint.2021.102525_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163144","article-title":"Safety and immunogenicity of Pfs25-EPA\/Alhydrogel(R), a transmission blocking vaccine against plasmodium falciparum: an open label study in malaria naive adults","volume":"11","author":"Talaat","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.parint.2021.102525_bb0125","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1473-3099(18)30344-X","article-title":"Safety and immunogenicity of Pfs25H-EPA\/Alhydrogel, a transmission-blocking vaccine against plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults","volume":"18","author":"Sagara","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"39","key":"10.1016\/j.parint.2021.102525_bb0130","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1016\/j.vaccine.2018.08.033","article-title":"Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: a phase 1 dose-escalation study in healthy adults","volume":"36","author":"Chichester","year":"2018","journal-title":"Vaccine"},{"issue":"38","key":"10.1016\/j.parint.2021.102525_bb0135","doi-asserted-by":"crossref","first-page":"19913","DOI":"10.1074\/jbc.M116.732305","article-title":"Structural and immunological characterization of recombinant 6-cysteine domains of the plasmodium falciparum sexual stage protein Pfs230","volume":"291","author":"MacDonald","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.parint.2021.102525_bb0140","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146221","article-title":"Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice","volume":"131","author":"Healy","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.parint.2021.102525_bb0145","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/14760584.2019.1674145","article-title":"Malaria transmission-blocking vaccines: wheat germ cell-free technology can accelerate vaccine development","volume":"18","author":"Miura","year":"2019","journal-title":"Expert Rev. Vaccines"},{"issue":"13","key":"10.1016\/j.parint.2021.102525_bb0150","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/j.vaccine.2020.02.011","article-title":"Evaluation of plasmodium vivax HAP2 as a transmission-blocking vaccine candidate","volume":"38","author":"Qiu","year":"2020","journal-title":"Vaccine"},{"issue":"6168","key":"10.1016\/j.parint.2021.102525_bb0155","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/333074a0","article-title":"A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains","volume":"333","author":"Kaslow","year":"1988","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.parint.2021.102525_bb0160","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/BF03401770","article-title":"Sequence polymorphism in two novel plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates","volume":"4","author":"Tsuboi","year":"1998","journal-title":"Mol. Med."},{"issue":"12","key":"10.1016\/j.parint.2021.102525_bb0165","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1128\/IAI.68.12.6618-6623.2000","article-title":"Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of plasmodium vivax to infect mosquitoes","volume":"68","author":"Hisaeda","year":"2000","journal-title":"Infect. Immun."},{"issue":"5","key":"10.1016\/j.parint.2021.102525_bb0170","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4269\/ajtmh.2003.69.536","article-title":"Blocking of transmission to mosquitoes by antibody to plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates","volume":"69","author":"Sattabongkot","year":"2003","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"23","key":"10.1016\/j.parint.2021.102525_bb0175","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1016\/S0264-410X(03)00258-5","article-title":"Serum antibodies induced by intranasal immunization of mice with plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes","volume":"21","author":"Arakawa","year":"2003","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.parint.2021.102525_bb0180","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1128\/IAI.00640-09","article-title":"Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection","volume":"77","author":"Arakawa","year":"2009","journal-title":"Infect. Immun."},{"issue":"9","key":"10.1016\/j.parint.2021.102525_bb0185","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1128\/IAI.00306-10","article-title":"Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization","volume":"78","author":"Miyata","year":"2010","journal-title":"Infect. Immun."},{"issue":"10","key":"10.1016\/j.parint.2021.102525_bb0190","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1128\/IAI.05214-11","article-title":"Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development","volume":"79","author":"Miyata","year":"2011","journal-title":"Infect. Immun."},{"issue":"4","key":"10.1016\/j.parint.2021.102525_bb0195","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1128\/CVI.00053-14","article-title":"Tricomponent complex loaded with a mosquito-stage antigen of the malaria parasite induces potent transmission-blocking immunity","volume":"21","author":"Arakawa","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.parint.2021.102525_bb0200","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fcimb.2019.00135","article-title":"A multi-stage plasmodium vivax malaria vaccine candidate able to induce long-lived antibody responses against blood stage parasites and robust transmission-blocking activity","volume":"9","author":"McCaffery","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"28","key":"10.1016\/j.parint.2021.102525_bb0205","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1016\/j.vaccine.2016.05.007","article-title":"Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against plasmodium vivax","volume":"34","author":"Blagborough","year":"2016","journal-title":"Vaccine"},{"issue":"23\u201324","key":"10.1016\/j.parint.2021.102525_bb0210","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.vaccine.2003.11.060","article-title":"Potent immunogenicity of DNA vaccines encoding plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy","volume":"22","author":"Kongkasuriyachai","year":"2004","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.parint.2021.102525_bb0215","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.1016\/j.vaccine.2010.06.100","article-title":"Intranasal and intramuscular immunization with Baculovirus dual expression system-based Pvs25 vaccine substantially blocks plasmodium vivax transmission","volume":"28","author":"Blagborough","year":"2010","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.parint.2021.102525_bb0220","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1128\/IAI.02040-14","article-title":"Baculovirus-vectored multistage plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites","volume":"82","author":"Mizutani","year":"2014","journal-title":"Infect. Immun."},{"issue":"15","key":"10.1016\/j.parint.2021.102525_bb0225","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/j.vaccine.2011.01.083","article-title":"Adenovirus-vectored plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine","volume":"29","author":"Miyata","year":"2011","journal-title":"Vaccine"},{"issue":"5 Suppl","key":"10.1016\/j.parint.2021.102525_bb0230","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4269\/ajtmh.2005.73.32","article-title":"Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a plasmodium vivax clinical grade PVS25 recombinant protein","volume":"73","author":"Arevalo-Herrera","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"2","key":"10.1016\/j.parint.2021.102525_bb0235","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4269\/ajtmh.2006.74.215","article-title":"Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees","volume":"74","author":"Collins","year":"2006","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"10","key":"10.1016\/j.parint.2021.102525_bb0240","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-3024.2007.00971.x","article-title":"Immunogenicity in rhesus of the plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720","volume":"29","author":"Saul","year":"2007","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.parint.2021.102525_bb0245","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1475-2875-6-107","article-title":"Transmission-blocking activity induced by malaria vaccine candidates Pfs25\/Pvs25 is a direct and predictable function of antibody titer","volume":"6","author":"Miura","year":"2007","journal-title":"Malar. J."},{"issue":"5","key":"10.1016\/j.parint.2021.102525_bb0250","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.vaccine.2006.09.035","article-title":"The use of transgenic plasmodium berghei expressing the plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials","volume":"25","author":"Ramjanee","year":"2007","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.parint.2021.102525_bb0255","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.vaccine.2004.12.019","article-title":"Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for plasmodium vivax malaria","volume":"23","author":"Malkin","year":"2005","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.parint.2021.102525_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002636","article-title":"Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51","volume":"3","author":"Wu","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.parint.2021.102525_bb0265","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/prep.2001.1613","article-title":"Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials","volume":"25","author":"Miles","year":"2002","journal-title":"Protein Expr. Purif."},{"issue":"4","key":"10.1016\/j.parint.2021.102525_bb0270","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/14760584.2017.1276833","article-title":"Towards clinical development of a Pfs48\/45-based transmission blocking malaria vaccine","volume":"16","author":"Theisen","year":"2017","journal-title":"Expert Rev. Vaccines"},{"issue":"3","key":"10.1016\/j.parint.2021.102525_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119335","article-title":"Recombinant Pvs48\/45 antigen expressed in E. coli generates antibodies that block malaria transmission in Anopheles albimanus mosquitoes","volume":"10","author":"Arevalo-Herrera","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.parint.2021.102525_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.634738","article-title":"Immunoreactivity of sera from low to moderate malaria-endemic areas against plasmodium vivax rPvs48\/45 proteins produced in Escherichia coli and Chinese Hamster ovary systems","volume":"12","author":"Arevalo-Herrera","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.parint.2021.102525_bb0285","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-018-0065-5","article-title":"Antibody targeting of a specific region of Pfs47 blocks plasmodium falciparum malaria transmission","volume":"3","author":"Canepa","year":"2018","journal-title":"NPJ Vaccines"},{"issue":"16","key":"10.1016\/j.parint.2021.102525_bb0290","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.vaccine.2015.03.008","article-title":"Plasmodium vivax gametocyte proteins, Pvs48\/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization","volume":"33","author":"Tachibana","year":"2015","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.parint.2021.102525_bb0295","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.vaccine.2012.01.003","article-title":"Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate","volume":"30","author":"Tachibana","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.parint.2021.102525_bb0300","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1128\/CVI.05104-11","article-title":"N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity","volume":"18","author":"Tachibana","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.parint.2021.102525_bb0305","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.3389\/fimmu.2019.02295","article-title":"Naturally acquired antibody response to malaria transmission blocking vaccine candidate Pvs230 domain 1","volume":"10","author":"Tentokam","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.parint.2021.102525_bb0310","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1128\/IAI.01056-13","article-title":"Functional comparison of plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay","volume":"81","author":"Miura","year":"2013","journal-title":"Infect. Immun."},{"issue":"33","key":"10.1016\/j.parint.2021.102525_bb0315","doi-asserted-by":"crossref","first-page":"13461","DOI":"10.1073\/pnas.0702239104","article-title":"Disruption of plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen","volume":"104","author":"Dinglasan","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.parint.2021.102525_bb0320","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1128\/IAI.01222-13","article-title":"Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of plasmodium falciparum and plasmodium vivax malaria","volume":"82","author":"Armistead","year":"2014","journal-title":"Infect. Immun."},{"issue":"27","key":"10.1016\/j.parint.2021.102525_bb0325","doi-asserted-by":"crossref","first-page":"16490","DOI":"10.1074\/jbc.M114.623165","article-title":"Anopheles midgut FREP1 mediates plasmodium invasion","volume":"290","author":"Zhang","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"28","key":"10.1016\/j.parint.2021.102525_bb0330","doi-asserted-by":"crossref","first-page":"11960","DOI":"10.1074\/jbc.M116.773564","article-title":"The fibrinogen-like domain of FREP1 protein is a broad-spectrum malaria transmission-blocking vaccine antigen","volume":"292","author":"Niu","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.parint.2021.102525_bb0335","doi-asserted-by":"crossref","first-page":"12569","DOI":"10.1038\/s41598-020-69513-x","article-title":"Evaluation and modeling of direct membrane-feeding assay with plasmodium vivax to support development of transmission blocking vaccines","volume":"10","author":"Miura","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parint.2021.102525_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.676276","article-title":"Viability and infectivity of plasmodium vivax gametocytes in short-term culture","volume":"11","author":"Ramos","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"6","key":"10.1016\/j.parint.2021.102525_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004807","article-title":"Optimization of a membrane feeding assay for plasmodium vivax infection in Anopheles albimanus","volume":"10","author":"Vallejo","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"1","key":"10.1016\/j.parint.2021.102525_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1383-5769(02)00037-5","article-title":"Transmission-blocking vaccine of vivax malaria","volume":"52","author":"Tsuboi","year":"2003","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.parint.2021.102525_bb0355","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-2815-6_8","article-title":"Membrane feeding assay to determine the infectiousness of plasmodium vivax gametocytes","volume":"1325","author":"Sattabongkot","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"9","key":"10.1016\/j.parint.2021.102525_bb0360","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1473-3099(09)70177-X","article-title":"Key gaps in the knowledge of plasmodium vivax, a neglected human malaria parasite","volume":"9","author":"Mueller","year":"2009","journal-title":"Lancet Infect. Dis."},{"issue":"2\u20133","key":"10.1016\/j.parint.2021.102525_bb0365","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijpara.2016.10.006","article-title":"Infectivity of symptomatic and asymptomatic plasmodium vivax infections to a southeast Asian vector, Anopheles dirus","volume":"47","author":"Kiattibutr","year":"2017","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.parint.2021.102525_bb0370","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/1475-2875-12-460","article-title":"Experimental plasmodium vivax infection of key Anopheles species from the Brazilian Amazon","volume":"12","author":"Rios-Velasquez","year":"2013","journal-title":"Malar. J."},{"key":"10.1016\/j.parint.2021.102525_bb0375","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12936-016-1104-1","article-title":"Plasmodium vivax gametocyte infectivity in sub-microscopic infections","volume":"15","author":"Vallejo","year":"2016","journal-title":"Malar. J."},{"issue":"2 Suppl","key":"10.1016\/j.parint.2021.102525_bb0380","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4269\/ajtmh.2011.09-0499","article-title":"Plasmodium vivax sporozoite production in Anopheles albimanus mosquitoes for vaccine clinical trials","volume":"84","author":"Solarte","year":"2011","journal-title":"Am. J.Trop. Med. Hyg."},{"key":"10.1016\/j.parint.2021.102525_bb0385","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1475-2875-11-70","article-title":"The biology of sexual development of plasmodium: the design and implementation of transmission-blocking strategies","volume":"11","author":"Sinden","year":"2012","journal-title":"Malar. J."},{"key":"10.1016\/j.parint.2021.102525_bb0390","first-page":"427","article-title":"The maintenance of a colony of Anopheles gambiae, with observations on the effects of changes in temperature","volume":"24","author":"Armstrong","year":"1961","journal-title":"Bull. World Health Organ."},{"issue":"1","key":"10.1016\/j.parint.2021.102525_bb0395","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1017\/S0031182000047375","article-title":"Gamete development in malaria parasites: bicarbonate-dependent stimulation by pH in vitro","volume":"76","author":"Nijhout","year":"1978","journal-title":"Parasitology"},{"issue":"5728","key":"10.1016\/j.parint.2021.102525_bb0400","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1126\/science.1108423","article-title":"Fungal pathogen reduces potential for malaria transmission","volume":"308","author":"Blanford","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.parint.2021.102525_bb0405","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jip.2005.10.006","article-title":"Infection of the malaria mosquito Anopheles gambiae with the entomopathogenic fungus Metarhizium anisopliae reduces blood feeding and fecundity","volume":"91","author":"Scholte","year":"2006","journal-title":"J. Invertebr. Pathol."},{"issue":"Suppl. 2","key":"10.1016\/j.parint.2021.102525_bb0410","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1590\/S0074-02761994000600024","article-title":"Development of sporogonic cycle of plasmodium vivax in experimentally infected Anopheles albimanus mosquitoes","volume":"89","author":"Salas","year":"1994","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"5 Suppl","key":"10.1016\/j.parint.2021.102525_bb0415","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4269\/ajtmh.2005.73.5_suppl.0730038","article-title":"Plasmodium vivax: transmission-blocking immunity in a malaria-endemic area of Colombia","volume":"73","author":"Arevalo-Herrera","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"3","key":"10.1016\/j.parint.2021.102525_bb0420","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2307\/3280753","article-title":"The Chesson strain of plasmodium vivax in Aotus monkeys and anopheline mosquitoes","volume":"66","author":"Collins","year":"1980","journal-title":"J. Parasitol."},{"issue":"2","key":"10.1016\/j.parint.2021.102525_bb0425","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4103\/0377-4929.48936","article-title":"Exflagellated microgametes of plasmodium vivax in human peripheral blood: a case report and review of the literature","volume":"52","author":"Tembhare","year":"2009","journal-title":"Indian J. Pathol. Microbiol."},{"issue":"5","key":"10.1016\/j.parint.2021.102525_bb0430","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01627-18","article-title":"Functional conservation of P48\/45 proteins in the transmission stages of plasmodium vivax (human malaria parasite) and P. berghei (murine malaria parasite)","volume":"9","author":"Cao","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.parint.2021.102525_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.parint.2020.102224","article-title":"Leveraging the wheat germ cell-free protein synthesis system to accelerate malaria vaccine development","volume":"80","author":"Kanoi","year":"2021","journal-title":"Parasitol. Int."},{"issue":"13","key":"10.1016\/j.parint.2021.102525_bb0440","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1093\/nar\/gkw536","article-title":"Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes: molecular insight into sex-specific processes and translational repression","volume":"44","author":"Lasonder","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.parint.2021.102525_bb0445","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41598-017-18840-7","article-title":"Probabilistic data integration identifies reliable gametocyte-specific proteins and transcripts in malaria parasites","volume":"8","author":"Meerstein-Kessel","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.parint.2021.102525_bb0450","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1074\/mcp.RA117.000036","article-title":"Functional characterization and comparison of plasmodium falciparum proteins as targets of transmission-blocking antibodies","volume":"19","author":"Nikolaeva","year":"2020","journal-title":"Mol. Cell. Proteomics"},{"issue":"1","key":"10.1016\/j.parint.2021.102525_bb0455","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41467-017-02646-2","article-title":"Unravelling the immune signature of plasmodium falciparum transmission-reducing immunity","volume":"9","author":"Stone","year":"2018","journal-title":"Nat. Commun."},{"issue":"45","key":"10.1016\/j.parint.2021.102525_bb0460","doi-asserted-by":"crossref","first-page":"6826","DOI":"10.1016\/j.vaccine.2018.08.058","article-title":"Comprehensive analysis of antibody responses to plasmodium falciparum erythrocyte membrane protein 1 domains","volume":"36","author":"Kanoi","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.parint.2021.102525_bb0465","doi-asserted-by":"crossref","first-page":"46086","DOI":"10.1038\/srep46086","article-title":"Immunoscreening of plasmodium falciparum proteins expressed in a wheat germ cell-free system reveals a novel malaria vaccine candidate","volume":"7","author":"Morita","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.parint.2021.102525_bb0470","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41591-020-0841-4","article-title":"Development and validation of serological markers for detecting recent plasmodium vivax infection","volume":"26","author":"Longley","year":"2020","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.parint.2021.102525_bb0475","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.parint.2021.102525_bb0480","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.parint.2021.102525_bb0485","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines","volume":"385","author":"Thompson","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.parint.2021.102525_bb0490","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41541-021-00345-0","article-title":"Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice","volume":"6","author":"Mallory","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"2","key":"10.1016\/j.parint.2021.102525_bb0495","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pt.2016.11.001","article-title":"Plasmodium vivax controlled human malaria infection - Progress and prospects","volume":"33","author":"Payne","year":"2017","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.parint.2021.102525_bb0500","article-title":"Safety and tolerability of mosquito-bite induced controlled human infection with P. vivax in Malaria-Naive study participants - Clinical profile and utility of molecular diagnostic methods","author":"Kamau","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.parint.2021.102525_bb0505","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jit394","article-title":"Experimentally induced blood-stage plasmodium vivax infection in healthy volunteers","volume":"208","author":"McCarthy","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.parint.2021.102525_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005139","article-title":"Safety and reproducibility of a clinical trial system using induced blood stage plasmodium vivax infection and its potential as a model to evaluate malaria transmission","volume":"10","author":"Griffin","year":"2016","journal-title":"PLoS Negl. Trop. Dis."}],"container-title":["Parasitology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383576921002439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383576921002439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:31:14Z","timestamp":1778520674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1383576921002439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":102,"alternative-id":["S1383576921002439"],"URL":"https:\/\/doi.org\/10.1016\/j.parint.2021.102525","relation":{},"ISSN":["1383-5769"],"issn-type":[{"value":"1383-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation","name":"articletitle","label":"Article Title"},{"value":"Parasitology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parint.2021.102525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102525"}}